CompletedPhase 2

Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)

United States427 participantsStarted 2023-04-18

Plain-language summary

This is an 8-week, double-blind, randomized placebo-controlled trial of the efficacy of a combination of extended-release naltrexone (XR-NTX) and extended-release buprenorphine (XR-BUP) compared to matched placebo injections (PBO-Inj) for the treatment of cocaine use disorder (CUD).

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Be 18 to 65 years of age;
✕. Be interested in reducing or stopping cocaine use.
✕. Be willing to comply with all study procedures and medication instructions.

What they're measuring

Proportion of Cocaine-negative UDS

Timeframe: Week 5 up to Week 8

Trial details

NCT IDNCT05262270

SponsorUniversity of Texas Southwestern Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-27

View on ClinicalTrials.gov More Cocaine Use Disorder trials